BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines gross Product Revenue Before Rebates & Returns ($M) ($M)
Form 10-Q / 10-K Revenue Note (XBRL)
Latest, Q2 2026
2,206
Period ended Jun 30, 2026
Change on a year earlier
+33.0%
1,658 in Q2 2025
History
31 quarters
Since Q2 2018
Sources
25
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Gross Product Revenue Before Rebates & Returns ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,206 | +33.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,894 | +35.2% | Form 10-Q (filed 2026-05-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,771 | +42.2% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,658 | +42.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,400 | +48.2% | Form 10-Q (filed 2026-05-06) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,246 | +70.3% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,167 | +74.9% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 945 | +85.3% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 811 | +101.7% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 732 | +83.6% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 667 | +94.6% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 510 | +72.5% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 402 | +60.1% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 398 | +93.4% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 343 | +131.2% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 295 | +105.9% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 251 | +131.3% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 206 | +116.2% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 148 | +119.1% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 144 | +169.7% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 109 | +83.9% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2020 | Sep 30, 2020 | 95.3 | +81.5% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 67.7 | +15.3% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 53.2 | -9.1% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 59 | +43.6% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 52.5 | +25.6% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 58.7 | +85.2% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 58.5 | – | Form 10-Q (filed 2020-05-11) ↗ |
| Q4 2018 | Dec 31, 2018 | 41.1 | – | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 41.8 | – | Form 10-Q (filed 2019-11-12) ↗ |
| Q2 2018 | Jun 30, 2018 | 31.7 | – | Form 10-Q (filed 2019-08-08) ↗ |
Breakdown
What makes up gross product revenue before rebates & returns ($m)
Cite this data
StockData. (2026). BeOne Medicines Gross Product Revenue Before Rebates & Returns ($M) ($M), quarterly Q2 2018–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/gtn_gross_rev
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.